Barclays acted as sole book running manager for the offering. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See the top stocks
Barclays acted as sole book running manager for the offering. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See the top stocks
Revance Therapeutics announced a proposed underwritten public offering of $100M of its common stock. The Company intends to use the net proceeds from the offering to advance the commercial growth
Guggenheim raised the firm’s price target on Revance to $16 from $15 and keeps a Buy rating on the shares as the firm is updating its model post Q4 results.
שינוי זה בא לאחר בדיקת ביצועי החברה ברבעון הרביעי. האנליסט מאמין שלמרות שמכירות עשויות לרדת ברבעון הראשון בשל מגמות עונתיות, הרבעון השני מציג הזדמנות משמעותית עבור Revance להגדיל את נתח
Goldman Sachs raised the firm’s price target on Revance to $9 from $8 and keeps a Neutral rating on the shares. The company’s Q4 results were in line with expectations,